ION expands ETF trading capabilities with Tradeweb integration
Johanna Roberts, Executive Vice President, General Counsel & Secretary at Penumbra Inc (NASDAQ:PEN), sold 590 shares of common stock on November 10, 2025, for a total of $160,188. The sales were executed in multiple transactions at prices ranging from $263.58 to $269.56.
The transactions, were disclosed in a Form 4 filing with the Securities and Exchange Commission.
Specifically, Roberts sold 11 shares at a weighted average price of $263.58, 13 shares at $264.89, 168 shares at $265.93, 211 shares at $266.72, 85 shares at $267.56, 76 shares at $269.01 and 36 shares at $269.56.
Following the transactions, Roberts directly owns 63,657 shares of Penumbra Inc , a portion of which are subject to vesting.
The sales were effected pursuant to a Rule 10b5-1 trading plan.
In other recent news, Penumbra reported strong third-quarter 2025 financial results, with revenue reaching $354.7 million, marking a 17.8% increase year-over-year and surpassing the forecast of $340.91 million. The company’s earnings per share also exceeded consensus estimates, leading management to raise its 2025 revenue guidance. Notably, Penumbra’s thrombectomy segment showed growth of 15% at constant currency, an improvement from the previous quarter. Following these results, Needham reiterated its Buy rating on Penumbra, setting a price target of $326.00.
Truist Securities also responded positively by raising its price target to $312.00, citing strong performance in the U.S. Embolization & Access segment and a 34% growth in venous thromboembolism, which offset slower U.S. stroke trends. Evercore ISI adjusted its price target slightly to $286.00, maintaining an Outperform rating due to the company’s 17% organic revenue growth and a 20.8% increase in its Embolization segment. These developments reflect a positive sentiment from analysts regarding Penumbra’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.